136 related articles for article (PubMed ID: 26651453)
1. Effect of Bosentan on Claudication Distance and Endothelium-Dependent Vasodilation in Hispanic Patients With Peripheral Arterial Disease.
De Haro J; Bleda S; Varela C; Esparza L; Acin F;
Am J Cardiol; 2016 Jan; 117(2):295-301. PubMed ID: 26651453
[TBL] [Abstract][Full Text] [Related]
2. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
Sfikakis PP; Papamichael C; Stamatelopoulos KS; Tousoulis D; Fragiadaki KG; Katsichti P; Stefanadis C; Mavrikakis M
Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
[TBL] [Abstract][Full Text] [Related]
3. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial.
Espinola-Klein C; Weisser G; Jagodzinski A; Savvidis S; Warnholtz A; Ostad MA; Gori T; Munzel T
Hypertension; 2011 Aug; 58(2):148-54. PubMed ID: 21646599
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Effects of Bosentan on Cardiovascular Events in Hispanic Patients with Intermittent Claudication: Four-Year Follow-up of the CLAU Trial : The CLAU Randomized Trial Long-Term Outcome.
De Haro J; Bleda S; Gonzalez-Hidalgo C; Michel I; Acin F
Am J Cardiovasc Drugs; 2019 Apr; 19(2):203-209. PubMed ID: 30417231
[TBL] [Abstract][Full Text] [Related]
5. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial.
Rafnsson A; Böhm F; Settergren M; Gonon A; Brismar K; Pernow J
Diabetologia; 2012 Mar; 55(3):600-7. PubMed ID: 22200728
[TBL] [Abstract][Full Text] [Related]
6. Impact of endothelin blockade on acute exercise-induced changes in blood flow and endothelial function in type 2 diabetes mellitus.
Schreuder TH; van Lotringen JH; Hopman MT; Thijssen DH
Exp Physiol; 2014 Sep; 99(9):1253-64. PubMed ID: 24928953
[TBL] [Abstract][Full Text] [Related]
7. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
[TBL] [Abstract][Full Text] [Related]
8. Extracorporeal shockwave therapy for intermittent claudication: Medium-term outcomes from a double-blind randomised placebo-controlled pilot trial.
Green JL; Harwood AE; Smith GE; Das T; Raza A; Cayton T; Wallace T; Carradice D; Chetter IC
Vascular; 2018 Oct; 26(5):531-539. PubMed ID: 29722640
[TBL] [Abstract][Full Text] [Related]
9. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication.
Gresele P; Migliacci R; Procacci A; De Monte P; Bonizzoni E
Thromb Haemost; 2007 Mar; 97(3):444-50. PubMed ID: 17334512
[TBL] [Abstract][Full Text] [Related]
10. The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans.
Böhm F; Settergren M; Gonon AT; Pernow J
Clin Sci (Lond); 2005 Apr; 108(4):357-63. PubMed ID: 15610070
[TBL] [Abstract][Full Text] [Related]
11. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.
Delis KT; Nicolaides AN; Wolfe JH; Stansby G
J Vasc Surg; 2000 Apr; 31(4):650-61. PubMed ID: 10753272
[TBL] [Abstract][Full Text] [Related]
12. Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design.
Fabry R; Monnet P; Schmidt J; Lusson JR; Carpentier PH; Baguet JC; Dubray C
Vasa; 2009 Aug; 38(3):213-24. PubMed ID: 19736632
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.
Packer M; McMurray JJV; Krum H; Kiowski W; Massie BM; Caspi A; Pratt CM; Petrie MC; DeMets D; Kobrin I; Roux S; Swedberg K;
JACC Heart Fail; 2017 May; 5(5):317-326. PubMed ID: 28449795
[TBL] [Abstract][Full Text] [Related]
14. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study.
Hebert A; Mikkelsen UR; Thilen U; Idorn L; Jensen AS; Nagy E; Hanseus K; Sørensen KE; Søndergaard L
Circulation; 2014 Dec; 130(23):2021-30. PubMed ID: 25446057
[TBL] [Abstract][Full Text] [Related]
15. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
[TBL] [Abstract][Full Text] [Related]
16. Preliminary evidence that low ankle-brachial index is associated with reduced bilateral hip extensor strength and functional mobility in peripheral arterial disease.
Parmenter BJ; Raymond J; Dinnen PJ; Lusby RJ; Fiatarone Singh MA
J Vasc Surg; 2013 Apr; 57(4):963-973.e1. PubMed ID: 23246081
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease.
Oka RK; Szuba A; Giacomini JC; Cooke JP
Vasc Med; 2005 Nov; 10(4):265-74. PubMed ID: 16444855
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.
Shahin Y; Cockcroft JR; Chetter IC
Br J Surg; 2013 Aug; 100(9):1154-63. PubMed ID: 23842829
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
[TBL] [Abstract][Full Text] [Related]
20. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
